You just read:

The New England Journal of Medicine Publishes Results from the Phase III ALSYMPCA Study of Xofigo® (radium Ra 223 dichloride) Injection

News provided by

Bayer HealthCare Pharmaceuticals Inc.

Jul 17, 2013, 17:01 ET